ClinicalTrials.gg
CompletedNCT01765569Updated Sep 23, 2015Results posted

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

A Phase 1 interventional study of Digoxin and Vemurafenib in Malignant Melanoma, Neoplasms, sponsored by Hoffmann-La Roche. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-23.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies testing vemurafenib in Melanoma — 2 open to participants now, 2 under way, 1 of them phase 3. Vemurafenib · Melanoma.

Enrollment
22nd of 56
29 · median 18
Started
2013
with 17 others
Phase 1
26 of 56
none open now
Registered
26th of 56
by date
Lead sponsor
23 of 56
Hoffmann-La Roche

Among the 56 studies testing vemurafenib in Melanoma, this one is the 22nd largest by enrollment, is one of 18 that started in 2013, is one of 26 in phase 1, and was the 26th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 56 studies testing vemurafenib in Melanoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About vemurafenib

Vemurafenib: first FDA approval 2011 (ZELBORAF), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing vemurafenib in Melanoma, or all of them as a file.
02

Study summary

This open-label, multi-center, three-period, one sequence study will investigate the effect of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF without acceptable standard treatment options. Patients will receive multiple doses of vemurafenib in Periods B and C and a single dose of digoxin in Periods A and C. Eligible patients will have the option to continue treatment with vemurafenib as part of an extension study (NCT01739764). The anticipated time on study treatment is approximately 36 days.

03

Conditions studied

  • Malignant Melanoma, Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients >= 18 years old
  • Patients with either unresectable Stage IIIc or Stage IV melanoma positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a DNA sequencing method, and who have no acceptable standard treatment options
  • (ECOG) performance status 0 to 2
  • >= 12 weeks
  • Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment
  • Adequate hematologic and end organ function
  • Female patients of and male patients with partners of childbearing potential must agree to always use two effective methods of
  • Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose of study drug
  • Prior anti-cancer therapy within 28 days before the first dose of study drug
  • History of cardiac or pulmonary dysfunction
  • History of symptomatic congestive heart failure of any class or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction within 6 months prior to first dose of study drug
  • Current dyspnea at rest, owing to complications of advanced or any requirement for supplemental oxygen to perform activities of daily living
  • History of congenital long syndrome or QTc > 450 ms
  • Current digoxin therapy or anticipated requirement to take digoxin therapy during the study
  • Active central nervous system lesions
  • Uncontrolled or poorly controlled diabetes
  • Current severe, uncontrolled systemic disease
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Vemurafenib + Digoxin

    Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.

    Drug: Digoxin · Drug: Vemurafenib

Interventions

  • Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.

  • Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin

    AUClast = Area under the plasma-concentration time curve from time zero to the last measurable plasma concentration which is presented in hour\*nanogram per milliliter (hour\*ng/mL). Hour 0 (H0) signified pre-dose sampling.

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  5. Maximum Plasma Concentration (Cmax) of Digoxin

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  6. Time to Maximum Plasma Concentration (Tmax) of Digoxin

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  7. Terminal Half-Life (t1/2) of Digoxin

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

  8. Apparent Clearance (CL/F) of Digoxin

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose

07

Results

Posted Aug 10, 2015

Participant flow

Period A
Participant flow — Period A
MilestoneVemurafenib + Digoxin
Started29
Completed29
Not completed0
Period B
Participant flow — Period B
MilestoneVemurafenib + Digoxin
Started29
Completed28
Not completed1
Withdrew: Withdrawal by subject1
Period C
Participant flow — Period C
MilestoneVemurafenib + Digoxin
Started28
Completed27
Not completed1
Withdrew: Death1

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin

AUClast = Area under the plasma-concentration time curve from time zero to the last measurable plasma concentration which is presented in hour\*nanogram per milliliter (hour\*ng/mL). Hour 0 (H0) signified pre-dose sampling.

Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin
hour*ng/mLPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin14.9 ± 4.2227.7 ± 10.6
Statistical analysis
  • Period A (Digoxin) vs Period C (Digoxin + Vemurafenib) · Geometric mean ratio: 1.82 · 90% CI 1.63 to 2.02
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin
Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin
hour*ng/mLPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin18.5 ± 4.6435.4 ± 4.16
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin
Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin
hour*ng/mLPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin7.73 ± 1.8610.6 ± 2.9
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin
Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin
hour*ng/mLPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin18.2 ± 4.8529.7 ± 9.62
PrimaryMaximum Plasma Concentration (Cmax) of Digoxin
Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Digoxin
ng/mLPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Maximum Plasma Concentration (Cmax) of Digoxin1.36 ± 0.4081.99 ± 0.562
Statistical analysis
  • Period A (Digoxin) vs Period C (Digoxin + Vemurafenib) · Geometric mean ratio: 1.47 · 90% CI 1.3 to 1.65
PrimaryTime to Maximum Plasma Concentration (Tmax) of Digoxin
Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Digoxin
hoursPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Time to Maximum Plasma Concentration (Tmax) of Digoxin1 (0.5 to 3)1 (0.47 to 2)
PrimaryTerminal Half-Life (t1/2) of Digoxin
Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · hours
Terminal Half-Life (t1/2) of Digoxin
hoursPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Terminal Half-Life (t1/2) of Digoxin35 ± 8.6756.4 ± 11
PrimaryApparent Clearance (CL/F) of Digoxin

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Reported as:
Mean · liters/hour
Apparent Clearance (CL/F) of Digoxin
liters/hourPeriod A (Digoxin)Period C (Digoxin + Vemurafenib)
Apparent Clearance (CL/F) of Digoxin14.5 ± 4.957.15 ± 0.808

Adverse events

Collected over From Screening to 28 days after the last dose of study treatment or until initiation of another anticancer therapy, whichever occurred first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period A—0/29 (0%)0/29 (0%)
Period B—2/29 (6.9%)20/29 (69%)
Period C—1/28 (3.6%)11/28 (39.3%)
Most frequent serious events
Most frequent serious events
EventPeriod APeriod BPeriod C
NeutropeniaBlood and lymphatic system disorders0/290/291/28
RashSkin and subcutaneous tissue disorders0/291/290/28
Upper respiratory tract infectionInfections and infestations0/291/290/28
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPeriod APeriod BPeriod C
RashSkin and subcutaneous tissue disorders0/297/293/28
ArthralgiaMusculoskeletal and connective tissue disorders0/295/292/28
AstheniaGeneral disorders0/291/294/28
MyalgiaMusculoskeletal and connective tissue disorders0/294/290/28
NauseaGastrointestinal disorders0/293/290/28
Rash maculo-papularSkin and subcutaneous tissue disorders0/293/290/28
PyrexiaGeneral disorders0/291/292/28
AlopeciaSkin and subcutaneous tissue disorders0/290/292/28
HyperkeratosisSkin and subcutaneous tissue disorders0/290/292/28
Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/292/290/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vemurafenib + Digoxin
Mean47.8 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Vemurafenib + Digoxin
Female16
Male13
08

Study locations

13 sites
  • Minsk District, 223040, Belarus
  • Minsk, BU-220013, Belarus
  • Vitebsk, BU-210603, Belarus
  • Haifa, 31096, Israel
  • Tel Aviv, 6423906, Israel
  • Tel Hashomer, 52661, Israel
  • Daegu, 702-911, Korea, Republic of
  • Seoul, 110-774, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Kazan, 420029, Russian Federation
  • Moscow, 115478, Russian Federation
  • St. Petersburg, 197758, Russian Federation
  • Johannesburg, 2193, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2013
First posted
Jan 10, 2013
Start
Jul 2013
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Aug 10, 2015
Last update
Sep 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01765569
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 10, 2013
Start date
Jul 2013
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Aug 10, 2015
Last update
Sep 23, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Vemurafenib

Start the discussion